摘要
Adoptive cell transfer(ACT)using chimeric antigen receptor(CAR)modified T cells and T cell receptor(TCR)engineered T cells has shown therapeutic efficacy in cancer treatment1,2.CAR T cells are widely applicable to tumor patients because of their ability to directly identify tumor cells in an MHCindependent manner.
基金
supported by grants from the National Natural Science Foundation of China(Grant Nos.82150108,31991171,and 81830002 to W.H.,and Grant No.82102892 to C.T.)。
